Theravance Biopharma (TBPH) Other Operating Expenses (2014 - 2026)

Theravance Biopharma (TBPH) has 11 years of Other Operating Expenses data on file, last reported at $1.0 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 77.24% YoY), and the FY2024 annual result was $4.5 million, changed N/A from the prior year.
• Other Operating Expenses grew to $1.0 million in Q1 2026 per TBPH's latest filing, from -$1000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $3.8 million in Q2 2022 and troughed at -$37.5 million in Q3 2022.
• A 4-year average of -$3.4 million and a median of $1.2 million in 2022 frame the typical range for Other Operating Expenses.
• On a YoY basis, Other Operating Expenses climbed as much as 175.51% in 2022 and fell as far as 175.51% in 2022.
• A 4-year view of Other Operating Expenses shows it stood at $1000.0 in 2022, then soared by 156100.0% to $1.6 million in 2024, then sank by 100.06% to -$1000.0 in 2025, then surged by 102900.0% to $1.0 million in 2026.
• Business Quant data shows TBPH's Other Operating Expenses at $1.0 million in Q1 2026, -$1000.0 in Q4 2025, and $1.6 million in Q3 2024.